Bionano Targets Adjusted EBITDA Neutrality as a Profitability Goal

Bionano Genomics, Inc. is targeting adjusted EBITDA neutrality, adding a profitability goal as it maintains 2026 revenue guidance of $31 million to $33 million.

Adjusted EBITDA measures earnings before interest, taxes, depreciation and amortization, with specified adjustments. Neutrality means reaching break-even on that adjusted measure.

Bionano’s third-quarter revenue rose 12%. Management warned that continued operations depended on raising additional funding amid expected losses and negative cash flows, as detailed in its third-quarter results.